Abstract Age-adjusted mortality rates for prostate cancer are higher for African-American men compared with those of European ancestry. Recent data suggest that West African men also have elevated risk for prostate cancer relative to European men. Genetic susceptibility to prostate cancer could account for part of this difference. We conducted a genome-wide association study (GWAS) of prostate cancer in West African men in the Ghana Prostate Study. Association testing was performed using multivariable logistic regression adjusted for age and genetic ancestry for 474 prostate cancer cases and 458 population-based controls on the Illumina HumanOmni-5 Quad BeadChip. The most promising association was at 10p14 within an intron of a long non-coding RNA (lncRNA RP11-543F8.2) 360 kb centromeric of GATA3 (p = 1.29E-7). In sub-analyses, SNPs at 5q31.3 were associated with high Gleason score (C7) cancers, the strongest of which was a missense SNP in PCDHA1 (rs34575154, p = 3.66E-8), and SNPs at Xq28 (rs985081, p = 8.66E-9) and 6q21 (rs2185710, p = 5.95E-8) were associated with low Gleason score (\7) cancers. We sought to validate our findings in silico in the African Ancestry Prostate Cancer GWAS Consortium, but only one SNP, at 10p14, replicated at p \ 0.05. Of the 90 prostate cancer loci reported from studies of men of 
Introduction
In the US, age-adjusted incidence rates of prostate cancer in African-Americans are twofold higher than those observed in men of European ancestry . Although age-adjusted estimates of prostate cancer from African cancer registries suggest lower rates for African men (Center et al. 2012; Chu et al. 2011) , international comparisons are complicated by population screening, overdiagnosis (Welch and Black 2010) , and incomplete cancer registration . Despite their challenges, mortality statistics can provide a stable and robust cancer statistic (Welch and Black 2010) , particularly for international comparisons. Age-adjusted mortality rates of prostate cancer show a pattern distinct from that of incidence (Center et al. 2012; Rebbeck et al. 2013) , with equal or higher rates in Africaand specifically, the West African region-compared with North America or Western Europe. Since West Africa is the principal ancestral origin of a substantial proportion of African-American men (Bryc et al. 2010; Torres et al. 2012) , one may hypothesize that genetic susceptibility loci that vary in allele frequency by ancestral population could account for part of the observed differences in prostate cancer rates within the US.
Recent genome-wide association studies (GWAS) have shown that genetic variants associated with prostate cancer-such as those at 8q24 (Amundadottir et al. 2006; Freedman et al. 2006; Haiman et al. 2007 ) and 17q21 (Haiman et al. 2011b )-are more common among AfricanAmericans compared with men of European ancestry. Whether the differences in susceptibility allele frequencies can partially explain differences in incidence across regions can best be answered by discovery of a larger fraction of the set of common variants associated with risk. To date, approximately 90 independent prostate cancer loci have been identified through GWAS, primarily in men of European background. Based on empiric analyses of existing data sets, it is estimated that these loci represent perhaps less than the total number of common variants, which could be even higher in men of African ancestry (Park et al. 2010) . To investigate genetic susceptibility to prostate cancer in West Africa, we conducted a GWAS in the Ghana Prostate Study, a collaboration involving the US National Cancer Institute (NCI) and the University of Ghana.
Methods

Study participants
Participants for analysis were recruited through the Ghana Prostate Study-a population-based component, and a clinical component. The population-based component was a probability sample designed using the 2000 Ghana Population and Housing Census data in an attempt to recruit approximately 1,000 men aged 50-74 years in the Greater Accra region (*3 million people) (Chokkalingam et al. 2012) , which successfully recruited 1,037 healthy men between 2004 and 2006 with a response percentage of 98.8 % (Chokkalingam et al. 2012) . Consented individuals underwent an in-person interview, and within 7 days had a digital rectal examination (DRE) and provided an overnight fasting blood sample for prostate-specific antigen (PSA) testing, biomarker assays, and genetic analysis. Subjects who had a positive screen by PSA ([2.5 ng/ml) or DRE underwent a transrectal ultrasound-guided biopsy. A total of 73 histologically confirmed prostate cancer cases were identified through the population-based screening component of the Ghana Prostate Study and are included in the case population analyzed herein. From the remaining 964 screen-negative individuals, 836 had at least 20 lg DNA extracted and available for analysis, and 500 of these were matched to cases for analysis by age (in 5-year categories).
In the Ghana Prostate Study, we recruited 676 prostate cancer cases at Korle Bu Teaching Hospital in Accra, Ghana, between 2008 and 2012. All consented cases were interviewed and provided an overnight fasting blood sample. At the time of selection for this analysis we had recruited 582 prostate cancer cases, from which we selected 427 for analysis. Combined with the 73 cases diagnosed through the population-based component of the study, this yielded 500 available prostate cancer cases for analysis. Five technical replicates for each of three individuals served as quality control (QC) samples.
This Ghana Prostate Study was approved by institutional review boards in Ghana and at the National Cancer Institute.
Genotyping and quality control DNA samples for this project were extracted from buffy coat samples using the Qiagen method according to the manufacturer's instructions. Pre-genotyping quality control metrics excluded six case samples and two controls. 494 prostate cancer cases, 498 screen-negative controls, plus 15 distinct quality control samples were genotyped on the Illumina HumanOmni5-Quad BeadChip (Clarke et al. 2012 ).
The initial overall completion rate of genotype calls was 97.38 %. After excluding 57,489 loci with no genotype call, the overall completion rate increased to 98.70 %. A total of 70,872 loci were excluded due to low completion rates (\90 %) and 1,393,418 single nucleotide polymorphisms (SNP) monomorphic in men from Ghana were further excluded. We advanced 2,837,019 SNPs for association analysis. For the quality control samples, which included three distinct samples each with five technical replicates, the concordance rate exceeded 99.99 %. Twenty-seven (7 cases, 20 controls) samples were excluded due to low completion rate (lower than 94 %) or extreme mean heterozygosity (lower than 13.5 % or greater than 16.5 %). A further five cases were excluded for having less than 80 % African ancestry using the HapMap build 26 data (CEU, JPT ? CHB, YRI) as the continental reference populations in a STRUCTURE analysis (Engelhardt and Stephens 2010) . Principal components analysis (PCA) identified 16 individuals (5 cases, 11 controls) with significant deviation of eigenvectors and thus, they were excluded (Reich et al. 2008) . Finally, unexpected relatedness (1st-2nd degree), assessed using the GLU qc.ibds module (http://code.google.com/p/glu-genetics/) with an IBD0 threshold of 0.70, was detected for 11 pairs of full-sibling and one monozygotic twin; one individual randomly chosen from each related group was retained while two cases and nine controls were excluded. Note that one nuclear family involved three individuals and accounted for three related pairs, so, a total of 11 individuals were removed. In addition, one case sample was excluded due to incomplete phenotype with missing age. The final analytic data set included 474 prostate cancer cases and 458 screen-negative controls.
Statistical analysis
Association tests for prostate cancer susceptibility were performed using multivariable unconditional logistic regression analyses (1 degree-of-freedom) adjusted for age and two eigenvectors (p \ 0.01 based on the null model) identified in PCA analysis. In addition, we stratified the analysis by Gleason score (B6, C7). Follow-up analyses were conducted in the African Ancestry Prostate Cancer GWAS Consortium using a total 5,096 cases and 4,972 controls (Haiman et al. 2011a, b) . Additional resources used for the analyses were dbSNP (Sherry et al. 2001) , 1,000 Genomes Project (Clarke et al. 2012) , GENCODE (Harrow et al. 2012) , HaploReg (Ward and Kellis 2012) , RegulomeDB (Boyle et al. 2012) , and Haploview 4.2 (Barrett et al. 2005) .
Results
The results of the scan are shown in Table 2 . In the Gleason score C7 stratum, the 5q31.3 locus reached genomewide statistical significance (5E-8) with the lowest p value being 3.66E-8 for rs34575154, a missense SNP in PCDHA1. In addition, SNPs at 22q13.31, 7q31.31 and 2q14.2 had p values less than E-7. In the Gleason score\7 stratum, seven loci were observed to have p values less than E-7, and two SNPs were below genome-wide statistical significance: rs985081 at Xq28 (p = 8.66E-9) and rs2185710 at 6q21 (p = 5.95E-8). We analyzed these SNPs stratified by Gleason score in the African Ancestry Prostate Cancer GWAS Consortium yet none of them replicated at p \ 0.05, although there was evidence for between-study heterogeneity of effect for several of these SNPs within the African-American data (Haiman et al. 2011a, b) .
Lastly, in our prostate cancer GWAS of African men we were able to assess 81 of the previously reported 90 prostate cancer susceptibility loci (Table 3) , and observed that 10 of these SNPs were statistically significant (p \ 0.05), including SNPs within ''Region 1'' (rs7017300, rs10090154) and ''Region 2'' (rs13254738, rs16901979) of the 8q24 region (Haiman et al. 2007) , as well as rs7210100 from the 17q21 region which was initially reported by the African Ancestry Prostate Cancer GWAS Consortium (Haiman et al. 2011b ). Other SNPs Hum Genet (2014) 133:509-521 511 Gene information curated from Haploreg, dbSNP, Ensembl, and GENCODE previously associated with prostate cancer, mostly in populations of European ancestry, did not replicate in our African population.
Discussion
In this GWAS of prostate cancer in West African men, there is evidence for an association between a possible new locus at 10p14 and prostate cancer. In an additional subanalysis, we observed SNPs at 5q31.3 associated with high Gleason score (C7) prostate cancers, and of SNPs at Xq28 and 6q21 in relation to low Gleason score (\7) prostate cancers; however, these observations require further confirmation because of the small sample size reported herein. Because of the noted racial disparities in prostate cancer incidence between men of European and African descent, this unique analysis may provide insight into prostate cancer pathogenesis, particularly for African populations. Lastly, of the 90 prostate cancer loci reported from studies of men of European, Asian or African-American ancestry,
we were able to test 81 in the Ghana Prostate Study, and 10 of these replicated at p \ 0.05, differences that may be partly ascribed to distinct genomic architecture (including different patterns of underlying linkage disequilibrium), heterogeneous prostate cancer populations, and uncharacterized gene-environment interactions. The strongest associated SNP, rs7918885, localizes to 10p14 and is approximately 360 kb 5 0 of GATA3 within an intron of the lncRNA gene RP11-543F8.2. An assessment of highly correlated SNPs using the 1,000 Genomes Project data did not reveal splice or exonic variants of RP11-543F8.2. In the NHGRI catalog of GWAS SNPs, the closest SNP associated with any cancer resides 227 kb away (Chung and Chanock 2011; Hindorff et al. 2009 ). The locus is marked by rs10795668 in a colorectal GWAS, but its underlying biology is still unknown (Tomlinson et al. 2008) . We also note that there is minimal linkage disequilibrium between that rs10795668 and rs7918885 (r 2 = 0.001 in scan control set); moreover, there are several recombination-hot spots between the two markers. Fig. 1 Association results, recombination plot and linkage disequilibrium structure for the 198.9-kb region of 10p14. Association results from a trend test in -log10 P values (y axis, left) of the SNPs are shown according to their chromosomal positions (x axis). The r 2 values were computed from rs7918885 to all of the other plotted SNPs to differentially size data points according to their level of linkage disequilibrium. SNPs that are highly correlated with rs7918885 (n = 6) were colored red. Linkage disequilibrium structure based on controls (n = 458) was visualized by snp.plotter software. The line graph shows likelihood ratio statistics (y axis, right) for recombination hotspot by SequenceLDhot software and 3 different colors represent 3 tests of 100 controls without resampling. Physical locations are based on NCBI Build 37 of the human genome. Gene annotation was based on ENCODE/GENCODE version 12 from the UCSC Genome Browser Hum Genet (2014) 133:509-521 513 Gene information curated from Haploreg, dbSNP, Ensembl, and GENCODE c Imputed using 1,000 Genomes Project data. Although we detected a promising association between the 10p14 SNPs and prostate cancer in this study of West African men, the highest p value did not quite reach the genome-wide threshold of 5 9 10 -8 . It is possible that the signal we have detected at 10p14 is due to chance, but more likely insufficient power to detect a low effect SNP (Donnelly 2008; Kraft and Hunter 2009 ). We had 64 % power to detect rs7918885 under 5E-8 based on the observed allele frequencies and odds ratio.
We did attempt to replicate the findings presented herein using a large meta-analytic dataset comprising AfricanAmericans-the African Ancestry Prostate Cancer GWAS Consortium-but only one SNP (rs2993385 at 10p14) replicated at p \ 0.05. There are three primary, nonmutually exclusive reasons why genetic signals may not be observed in the ancestrally related, but distinct, AfricanAmerican population. The first reason is that the genomic architecture of African-American men is distinct from that of African men. A recent analysis estimated that the African-American population has continuously received gene flow from European populations over 14 generations ) that has resulted in the African-American population having mean ancestral percentages of 75 % West African, 20 % European, and 5 % Native American (Bryc et al. 2010; Tishkoff et al. 2009; Zakharia et al. 2009 ). Individuals who self-identify as African-American are highly variable in degree of West African admixture (Bryc et al. 2010; Henn et al. 2010; Jin et al. 2012; Tishkoff et al. 2009 ). There are also large differences in allele frequencies (Adeyemo and Rotimi 2010; Ntzani et al. 2012) , private SNPs (Campbell and Tishkoff 2008; Conrad et al. 2006) , patterns of homozygosity (Pemberton et al. 2012) , and LD structure (Campbell and Tishkoff 2008; Conrad et al. 2006 ) between African and African-American populations. Although it is important to note that African ancestry of African-Americans is most similar to the nonBantu Niger-Kordofanian population of West Africa (Bryc et al. 2010; Tishkoff et al. 2009 ), tribes of which overlap with the geographical location of the Ghana Prostate Study.
The second reason is screening. In the United States the use of DRE and PSA screening has been widespread and has resulted in overdiagnosis (Welch and Black 2010 ) and a concurrent change in Gleason score distribution. SEER data indicate that, of the black men diagnosed with prostate cancer during 2003-2008, 1 % was reported with Gleason 2-4, 48 % with Gleason 5-6, and 51 % with Gleason 7-10. Respective percentages for the 474 Ghanaian cases in the study were 1, 29 and 70 %. The greater proportion of advanced grades may be expected given that only 70 cases in the final analysis were detected through the population screening component of our study; a majority of the remaining 404 were symptomatic cases who presented at the clinic; the prevalence of PSA screening in Ghana, during the study period, was low (4 vs. [50 % in US). Thus, the majority of our case population comprises symptomatic disease rather than screen-detected cancers, which is especially important for this malignancy given it is expected to develop in up to 80 % of men by age 80 years (Franks 1954; Haas et al. 2008; Sakr et al. 1993) .
The third reason could be related to uncharacterized gene-environment interactions (Hemminki et al. 2006; Perez-Losada et al. 2011) . In support of a strong environmental component is the fact prostate cancer mortality rates in the US are geographically variable both between and within racial groups, 1 yet neither migration patterns (Tolnay 2003) nor genetic diversity (Zakharia et al. 2009 ) of the African-American population can account for such patterns and trends.
Differences in population genetics, environments, and disease spectra can account for differences in observed associations with complex diseases across ancestrally diverse groups (Ioannidis 2007; Ntzani et al. 2012) . For example, the African Ancestry Prostate Cancer GWAS Consortium replicated approximately half of the 49 SNPs previously associated and validated in populations of European ancestry (Haiman et al. 2011a ). Other studies of European sub-populations (Gaj et al. 2012; Vijai et al. 2011) , Asian populations Takata et al. 2010 ) and populations of African descent (Chang et al. 2005; Xu et al. 2011 ) have reported similar results. Conversely, prostate cancer risk loci discrete to specific nonCaucasian populations have also been described (Akamatsu et al. 2012; Batra et al. 2011; Haiman et al. 2011b; Takata et al. 2010; Wang et al. 2012 ). In addition, functional studies support the idea that some of these differences by ancestry may have a biological grounding (Grisanzio et al. 2012) .
In summary, we present evidence for a promising novel prostate cancer locus at 10p14 in a West African population in our initial GWAS. Further studies of prostate cancer in West African men are required for validation of this locus as well as those associated with low or high Gleason score prostate cancers. Further efforts are required to recruit greater numbers of cases in high-quality epidemiologic studies to investigate the underlying genetics-and in turn gene-environment interactions-of a complex disease such as prostate cancer. 
